Zusammenfassung
Die Milz hat eine zentrale immunologische Funktion im allgemeinen Kontext der B-Zellentwicklung, der Antigenpräsentation und der damit verbundenen Reifung des Immunsystems, die zudem insbesondere bei der Abwehr bekapselter Bakterien zum Tragen kommt. Darüber hinaus ist die Milz der zentrale Abbauort für gealterte, intrinsisch defekte, durch Antikörper opsonierte oder durch andere externe Einflüsse veränderte Blutzellen. Aus diesen Funktionen ergibt sich einerseits die Bedeutung der vollständigen oder partiellen Splenektomie für hämatologische Erkrankungen sowie andererseits das damit verbundene potenzielle Risiko für Spätfolgen. In diesem Kapitel werden zunächst die potenziellen, mit einer Splenektomie assoziierten Risiken und Komplikationen dargestellt und Empfehlungen zur Prophylaxe der Postsplenektomie-Infektionen diskutiert. Anschließend werden Vorgehensweisen zur Splenektomie aus hämatologischer Sicht skizziert, bevor in Einzelabschnitten eine Darstellung spezifischer Krankheitsbilder einschließlich der Rolle der vollständigen oder partiellen bzw. subtotalen Splenektomie in der Behandlung von Patienten mit diesen Erkrankungen erfolgt.
Literatur
Alizai NK, Richards EM, Stringer MD (2010) Is cholecystectomy really an indication for concomitant splenectomy in mild hereditary spherocytosis? Arch Dis Child 95:596–599
Andolfo I, Russo R, Gambale A, Iolascon A (2016) New insights on hereditary erythrocyte membrane defects. Haematologica 101:1284–1294
Aydinok Y, Bayraktaroglu S, Yildiz D, Alper H (2011) Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 33:374–378
Bader-Meunier B, Gauthier F, Archambaud F, Cynober T, Mielot F, Dommergues JP, Warszawski J, Mohandas N, Tchernia G (2001) Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 97:399–403
Beutler E, Gelbart T (2000) Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 95:3585–3588
Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ (2004) Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 126:455–474
Brousse V, Buffet P, Rees D (2014) The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol 166:165–176
Cappellini MD, Fiorelli G (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64–74
Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (2014) Guidelines for the management of transfusion dependent thalassemia (TDT). Thalassemia International Federation, Nicosia
Cario H, Kohne E (2016) AWMF S1-Leitlinie: Thalassämien. AWMF online http://www.awmf.org/leitlinien/detail/ll/025-017.html. Zugegriffen am 15.04.2018.
Cooper N (2017) State of the art – how I manage immune thrombocytopenia. Br J Haematol 177:39–54
Davies JM, Lewis MP, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PH (2011) Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British committee for standards in haematology by a working party of the haemato-oncology task force. Br J Haematol 155:308–317
Deutsche Gesellschaft für Infektiologi (DGI) e.V. (2017) Asplenie-Net. Prävention bei Splenektomie und Asplenie. https://asplenie-net.org/
Eber S (2006) Angeborene Erythrozytenmembrandefekte. In: Gadener H, Gaedicke G, Niemeyer C (Hrsg) Pädiatrische Hämatologie und Onkologie. Springer Medizin Verlag, Heidelberg, S 123–138
Eber S, Andres O (2016) S1-Leitlinie: Hereditäre Sphärozytose. AWMF online http://www.awmf.org/leitlinien/detail/ll/025-087.html
Eber S, Lux SE (2004) Hereditary spherocytosis – defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 41:118–141
Engelhardt M, Eber S, Germing U, Heimpel H, Kern WV, Schmugge M (2013) Prävention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie. Onkopedia Online https://www.onkopedia.com/de/onkopedia/guidelines/praevention-von-infektionen-und-thrombosen-nach-splenektomie-oder-funktioneller-asplenie/@@view/html/index.html
Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Jason Smithers C, Brown RL et al (2016) Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg 51:122–127
Guizzetti L (2016) Total versus partial splenectomy in pediatric hereditary spherocytosis: a systematic review and meta-analysis. Pediatr Blood Cancer 63:1713–1722
Hamilton JW, Jones FG, McMullin MF (2004) Glucose-6-phosphate dehydrogenase Guadalajara – a case of chronic non-spherocytic haemolytic anaemia responding to splenectomy and the role of splenectomy in this disorder. Hematology 9:307–309
Harteveld CL, Higgs DR (2010) Alpha-thalassaemia. Orphanet J Rare Dis 5:13
Heimpel H, Anselstetter V, Chrobak L, Denecke J, Einsiedler B, Gallmeier K, Griesshammer A, Marquardt T, Janka-Schaub G, Kron M et al (2003) Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood 102:4576–4581
Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A (2017) The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 176:395–411
Iolascon A, Heimpel H, Wahlin A, Tamary H (2013) Congenital dyserythropoietic anemias: molecular insights and diagnostic approach. Blood 122:2162–2166
Iolascon A, Andolfo I, Barcellini W, Corcione F, Garcon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC et al (2017) Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica 102:1304–1313
Krauth MT, Lechner K, Neugebauer EA, Pabinger I (2008) The postoperative splenic/portal vein thrombosis after splenectomy and its prevention – an unresolved issue. Haematologica 93:1227–1232
Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O (2014) Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 99:392–398
Kung C, Hixon J, Kosinski PA, Cianchetta G, Histen G, Chen Y, Hill C, Gross S, Si Y, Johnson K et al (2017) AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood 130:1347–1356
Lobitz S, Cario H, Grosse R, Jarisch A, Kulozik AE, Kunz J (2014) AWMF S2k-Leitlinie 025/016: Sichelzellkrankheit. AWMF online http://www.awmf.org/leitlinien/detail/ll/025-016.html
Marchetti M, Quaglini S, Barosi G (1998) Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. J Intern Med 244:217–226
Miano M (2016) How I manage Evans syndrome and AIHA cases in children. Br J Haematol 172:524–534
Morris CR, Vichinsky EP (2010) Pulmonary hypertension in thalassemia. Ann N Y Acad Sci 1202:205–213
Mouttalib S, Rice HE, Snyder D, Levens JS, Reiter A, Soler P, Rothman JA, Thornburg CD (2012) Evaluation of partial and total splenectomy in children with sickle cell disease using an Internet-based registry. Pediatr Blood Cancer 59:100–104
Piel FB, Weatherall DJ (2014) The alpha-thalassemias. N Engl J Med 371:1908–1916
Pincez T, Guitton C, Gauthier F, de Lambert G, Picard V, Feneant-Thibault M, Turhan A, Mohandas N, Tchernia G, Garcon L (2016) Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study. Blood 127:1616–1618
Rao VK (2015) Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr 3:65
Rogulski R, Adamowicz-Salach A, Matysiak M, Piotrowski D, Gogolewski M, Piotrowska A, Roik D, Kaminski A (2016) Laparoscopic splenectomy for hereditary spherocytosis-preliminary report. Eur J Haematol 96:637–642
Rund D, Rachmilewitz E (2005) Beta-thalassemia. N Engl J Med 353:1135–1146
Russo R, Gambale A, Langella C, Andolfo I, Unal S, Iolascon A (2014) Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: definition of clinical and molecular spectrum and identification of new diagnostic scores. Am J Hematol 89:E169–E175
Schilling RF, Gangnon RE, Traver MI (2008) Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 6:1289–1295
Slater BJ, Chan FP, Davis K, Dutta S (2010) Institutional experience with laparoscopic partial splenectomy for hereditary spherocytosis. J Pediatr Surg 45:1682–1686
Stewart GW, Amess JA, Eber SW, Kingswood C, Lane PA, Smith BD, Mentzer WC (1996) Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 93:303–310
Stoehr GA, Sobh JN, Luecken J, Heidemann K, Mittler U, Hilgers R, Eber SW (2006) Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity. Br J Haematol 132:791–793
Strasser BM, Holschneider AM (1986) Die Milz: Funktion, Erkrankungen, Chirurgie und Replantation. Hippocrates Verlag, Stuttgart
Stuart MJ, Nagel RL (2004) Sickle-cell disease. Lancet 364:1343–1360
Taher A, Tyan PI (2014) The Spleen. In: Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (Hrsg) Guidelines for the management of transfusion dependent thalassemia (TDT). Thalassemia International Federation, Nicosia, S 126–132
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115:1886–1892
Taher AT, Musallam KM, Cappellini MD, Weatherall DJ (2011) Optimal management of beta thalassaemia intermedia. Br J Haematol 152:512–523
Taher A, Vichinsky E, Musallam KM, Cappellini MD, Viprakasit V (2013) Splenectomy. In: Taher A, Vichinsky E, Musallam KA, Cappellini MD, Viprakasit V (Hrsg) Guidelines for the management of non transfusion dependent thalassemia. Thalassemia International Federation, Nicosia, S 19–26
Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sorensen HT (2010) Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 8:1413–1416
Williamson D (1993) The unstable haemoglobins. Blood Rev 7:146–163
Zanella A, Fermo E, Bianchi P, Valentini G (2005) Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 130:11–25
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Cario, H. (2018). Splenektomie bei Kindern und Jugendlichen mit hämatologischen Erkrankungen. In: von Schweinitz, D., Ure, B. (eds) Kinderchirurgie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53390-1_7-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-53390-1_7-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-53390-1
Online ISBN: 978-3-662-53390-1
eBook Packages: Springer Referenz Medizin